Atypical antipsychotic (English Wikipedia)

"Drug Product Database Online Query". Government of Canada, Health Canada, Public Affairs, Consultation and Regions Branch. April 25, 2012. Retrieved February 1, 2018.

cardiosmart.org

"norepinephrine". Cardiosmart.org. December 15, 2010. Retrieved September 30, 2016.

diabetesupdate.blogspot.se

"Diabetes Update: Hunger is a Symptom". Diabetesupdate.blogspot.se. August 8, 2007. Retrieved September 30, 2016.

doi.org

Miyake N, Miyamoto S, Jarskog LF (October 2012). "New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?". Clinical Schizophrenia & Related Psychoses. 6 (3): 122–33. doi:10.3371/CSRP.6.3.4. PMID 23006237.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842. S2CID 1071537.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
"A roadmap to key pharmacologic principles in using antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 9 (6): 444–54. 2007. doi:10.4088/PCC.v09n0607. PMC 2139919. PMID 18185824.
Tyrer P, Kendall T (January 2009). "The spurious advance of antipsychotic drug therapy". Lancet. 373 (9657): 4–5. doi:10.1016/S0140-6736(08)61765-1. PMID 19058841. S2CID 19951248.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. (September 2011). "Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis". JAMA. 306 (12): 1359–69. doi:10.1001/jama.2011.1360. PMID 21954480.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H (August 2017). "Treatment of negative symptoms: Where do we stand, and where do we go?" (PDF). Schizophrenia Research. 186: 55–62. doi:10.1016/j.schres.2016.05.015. PMID 27293137. S2CID 4907333.
Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (July 2015). "Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials". Schizophrenia Bulletin. 41 (4): 892–9. doi:10.1093/schbul/sbu170. PMC 4466178. PMID 25528757.
Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. (November 2016). "Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?". The British Journal of Psychiatry (Submitted manuscript). 209 (5): 361–365. doi:10.1192/bjp.bp.116.182683. PMID 27802977.
van Os J, Kapur S (August 2009). "Schizophrenia". Lancet. 374 (9690): 635–45. doi:10.1016/S0140-6736(09)60995-8. PMID 19700006. S2CID 208792724.
Kane JM, Correll CU (2010). "Pharmacologic treatment of schizophrenia". Dialogues in Clinical Neuroscience. 12 (3): 345–57. doi:10.31887/DCNS.2010.12.3/jkane. PMC 3085113. PMID 20954430.
Siskind D, McCartney L, Goldschlager R, Kisely S (November 2016). "Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis". The British Journal of Psychiatry. 209 (5): 385–392. doi:10.1192/bjp.bp.115.177261. PMID 27388573.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH (2015). "A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes". Schizophrenia Bulletin. 41 (6): 1227–1236. doi:10.1093/schbul/sbv125. ISSN 1745-1701. PMC 4601722. PMID 26338693.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B (April 23, 2020). "Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone". The International Journal of Neuropsychopharmacology. 23 (4): 217–229. doi:10.1093/ijnp/pyaa004. ISSN 1469-5111. PMC 7177160. PMID 31974576.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (February 2011). "Increasing off-label use of antipsychotic medications in the United States, 1995-2008". Pharmacoepidemiology and Drug Safety. 20 (2): 177–84. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Geddes J, Freemantle N, Harrison P, Bebbington P (December 2000). "Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis". BMJ. 321 (7273): 1371–6. doi:10.1136/bmj.321.7273.1371. PMC 27538. PMID 11099280.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (September 2005). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". The New England Journal of Medicine. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203.
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. (April 2006). "Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic". The American Journal of Psychiatry. 163 (4): 611–22. doi:10.1176/appi.ajp.163.4.611. PMID 16585435.
Voruganti LP, Baker LK, Awad AG (March 2008). "New generation antipsychotic drugs and compliance behaviour". Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660. S2CID 34935.
Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (January 2012). "Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications". The International Journal of Risk & Safety in Medicine. 24 (3): 137–46. doi:10.3233/JRS-2012-0567. PMID 22936056.
Owens DC (2008). "How CATIE brought us back to Kansas: A critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia". Advances in Psychiatric Treatment. 14: 17–28. doi:10.1192/apt.bp.107.003970.
Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). "Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)". Neuropsychobiology. 57 (1–2): 80–7. doi:10.1159/000135641. PMID 18515977. S2CID 2669203.
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Nelson JC, Papakostas GI (September 2009). "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials". The American Journal of Psychiatry. 166 (9): 980–91. doi:10.1176/appi.ajp.2009.09030312. PMID 19687129.
Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC (December 2015). "Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study". The American Journal of Psychiatry. 172 (12): 1251–8. doi:10.1176/appi.ajp.2015.14101251. PMC 4843798. PMID 26085041.
Maneeton N, Maneeton B, Srisurapanont M, Martin SD (September 2012). "Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials". BMC Psychiatry. 12: 160. doi:10.1186/1471-244X-12-160. PMC 3549283. PMID 23017200.
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. (August 2004). "A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". Journal of Clinical Psychopharmacology. 24 (4): 365–73. doi:10.1097/01.jcp.0000130557.08996.7a. PMID 15232326. S2CID 36295165.
Roberts RJ, Lohano KK, El-Mallakh RS (September 2016). "Antipsychotics as antidepressants". Asia-Pacific Psychiatry. 8 (3): 179–88. doi:10.1111/appy.12186. PMID 25963405. S2CID 24264818.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–15. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Bishara D, Taylor D (2009). "Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder". Neuropsychiatric Disease and Treatment. 5: 483–90. doi:10.2147/ndt.s5742. PMC 2762364. PMID 19851515.
Taylor DM, Cornelius V, Smith L, Young AH (December 2014). "Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis". Acta Psychiatrica Scandinavica. 130 (6): 452–69. doi:10.1111/acps.12343. PMID 25283309. S2CID 23324764.
Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J (June 2011). "Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials". BMC Psychiatry. 11: 101. doi:10.1186/1471-244X-11-101. PMC 3152513. PMID 21689438.
Kishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials". CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID 23812802. S2CID 11543666.
Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP (February 2003). "Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths". Primary Care Companion to the Journal of Clinical Psychiatry. 5 (1): 6–14. doi:10.4088/PCC.v05n0103. PMC 353028. PMID 15156241.
Uçok A, Gaebel W (February 2008). "Side effects of atypical antipsychotics: a brief overview". World Psychiatry. 7 (1): 58–62. doi:10.1002/j.2051-5545.2008.tb00154.x. PMC 2327229. PMID 18458771.
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC (January 2010). "Impact of FDA black box advisory on antipsychotic medication use". Archives of Internal Medicine. 170 (1): 96–103. doi:10.1001/archinternmed.2009.456. PMC 4598075. PMID 20065205.
Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. (July 2014). "Comparative mortality risks of antipsychotic medications in community-dwelling older adults". The British Journal of Psychiatry. 205 (1): 44–51. doi:10.1192/bjp.bp.112.122499. PMID 23929443.
Steinberg M, Lyketsos CG (September 2012). "Atypical antipsychotic use in patients with dementia: managing safety concerns". The American Journal of Psychiatry. 169 (9): 900–6. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Alevizos B, Papageorgiou C, Christodoulou GN (September 1, 2004). "Obsessive-compulsive symptoms with olanzapine". The International Journal of Neuropsychopharmacology. 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni G, Narayanaswamy JC, Math SB (January 1, 2012). "Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia". Indian Journal of Pharmacology. 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMC 3480803. PMID 23112432.
Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A (September 1, 2000). "Olanzapine and obsessive-compulsive symptoms". European Neuropsychopharmacology. 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610. S2CID 276209.
Schirmbeck F, Zink M (March 1, 2012). "Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review". Current Neuropharmacology. 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMC 3286851. PMID 22942882.
Seeman P (February 2002). "Atypical antipsychotics: mechanism of action". Canadian Journal of Psychiatry. 47 (1): 27–38. doi:10.1177/070674370204700106. PMID 11873706.
Correll CU, Schenk EM (March 2008). "Tardive dyskinesia and new antipsychotics". Current Opinion in Psychiatry. 21 (2): 151–6. doi:10.1097/YCO.0b013e3282f53132. PMID 18332662. S2CID 37288246.
"Consensus development conference on antipsychotic drugs and obesity and diabetes". Diabetes Care. 27 (2): 596–601. February 2004. doi:10.2337/diacare.27.2.596. PMID 14747245.
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, et al. (May 2013). "Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model". Schizophrenia Research. 146 (1–3): 162–9. doi:10.1016/j.schres.2013.02.023. PMID 23499243. S2CID 43719333.
Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A (August 1, 2018). "Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis". Journal of Comparative Effectiveness Research. 7 (8): 737–748. doi:10.2217/cer-2018-0016. ISSN 2042-6305. PMID 29697278. S2CID 13769615.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 1, 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. ISSN 2215-0366. PMC 7029416. PMID 31860457. S2CID 209434994.
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA (2017). "Antipsychotic-associated weight gain: management strategies and impact on treatment adherence". Neuropsychiatr Dis Treat. 13: 2231–2241. doi:10.2147/NDT.S113099. PMC 5574691. PMID 28883731.
Satlin A, Durgam S, Vanover KE, Davis RE, Huo J, Mates S, Correll C (May 2020). "M205. Long-Term Safety of Lumateperone (ITI-007): Metabolic Effects in a 1-Year Study". Schizophr Bull. 46 (Suppl 1): S214. doi:10.1093/schbul/sbaa030.517. PMC 7234755.
Wang Y, Wang D, Cheng J, Fang X, Chen Y, Yu L, Ren J, Tian Y, Zhang C (September 2021). "Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis". Journal of Psychopharmacology. 35 (9): 1111–9. doi:10.1177/02698811211035391. PMID 34311625. S2CID 236451973.
Goldstein BI, Baune BT, Bond DJ, Chen PH, Eyler L, Fagiolini A, Gomes F, Hajek T, Hatch J, McElroy SL, McIntyre RS, Prieto M, Sylvia LG, Tsai SY, Kcomt A, Fiedorowicz JG (August 2020). "Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders". Bipolar Disorders. 22 (5): 440–460. doi:10.1111/bdi.12921. hdl:11343/251495. PMC 7522687. PMID 32356562.
Park YW, Kim Y, Lee JH (December 2012). "Antipsychotic-induced sexual dysfunction and its management". The World Journal of Men's Health. 30 (3): 153–9. doi:10.5534/wjmh.2012.30.3.153. PMC 3623530. PMID 23596605.
Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136. S2CID 262520276.
Holm AC, Edsman I, Lundberg T, Odlind B (June 1993). "Tolerability of remoxipride in the long term treatment of schizophrenia. An overview". Drug Safety. 8 (6): 445–56. doi:10.2165/00002018-199308060-00005. PMID 8329149. S2CID 43855244.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Egerton A, Ahmad R, Hirani E, Grasby PM (November 2008). "Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat". Psychopharmacology. 200 (4): 487–96. doi:10.1007/s00213-008-1226-4. PMID 18597077. S2CID 11800154.
de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–39. doi:10.1016/j.ejphar.2005.09.065. PMID 16310183.
King MV, Marsden CA, Fone KC (September 2008). "A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory". Trends in Pharmacological Sciences. 29 (9): 482–92. doi:10.1016/j.tips.2008.07.001. PMID 19086256.
Shahid M, Walker GB, Zorn SH, Wong EH (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". Journal of Psychopharmacology. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID 18308814. S2CID 206489515.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–81. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–23. doi:10.1016/0014-2999(88)90651-6. PMID 2842163.
Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–6. doi:10.1016/j.autneu.2008.06.004. PMID 18667366. S2CID 20878941.
Weber S, Volynets V, Kanuri G, Bergheim I, Bischoff SC (December 2009). "Treatment with the 5-HT3 antagonist tropisetron modulates glucose-induced obesity in mice". International Journal of Obesity. 33 (12): 1339–47. doi:10.1038/ijo.2009.191. PMID 19823183.
Gobbi G, Janiri L (December 1999). "Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study". European Neuropsychopharmacology. 10 (1): 43–9. doi:10.1016/S0924-977X(99)00055-3. PMID 10647096. S2CID 24251712.
Navari RM (January 2014). "Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting". European Journal of Pharmacology. 722: 180–6. doi:10.1016/j.ejphar.2013.08.048. PMID 24157985.
Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". CNS Drugs. 24 (1): 65–84. doi:10.2165/11202620-000000000-00000. PMID 20030420. S2CID 23464075.
Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
Tanaka O, Kondo T, Otani K, Yasui N, Tokinaga N, Kaneko S (February 1998). "Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects". Therapeutic Drug Monitoring. 20 (1): 117–9. doi:10.1097/00007691-199802000-00021. PMID 9485566.
Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID 6931472.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID 3545764.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID 7185768.
Farah A (2005). "Atypicality of atypical antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (6): 268–74. doi:10.4088/PCC.v07n0602. PMC 1324958. PMID 16498489.
Weiden PJ (January 2007). "EPS profiles: the atypical antipsychotics are not all the same". Journal of Psychiatric Practice. 13 (1): 13–24. doi:10.1097/00131746-200701000-00003. PMID 17242588. S2CID 46319827.
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. (October 2006). "Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)". Archives of General Psychiatry. 63 (10): 1079–87. doi:10.1001/archpsyc.63.10.1079. PMID 17015810.
Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM (2023). "Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients". The Primary Care Companion for CNS Disorders. 25 (1): 45835. doi:10.4088/PCC.22m03331. ISSN 2155-7780. PMID 36821764.

drugs.com

"Respiridone". The American Society of Health-System Pharmacists. Retrieved April 3, 2011.

europa.eu

ema.europa.eu

"European Medicines Agency: Search". European Medicines Agency. Archived from the original on May 26, 2012. Retrieved February 2, 2018. Search

fda.gov

Research Cf. "Drug Approvals and Databases - Drug Trials Snapshots: REXULTI for the treatment of major depressive disorder". www.fda.gov. Retrieved October 18, 2018.
"FDA : Psychopharmacological Drugs Advisory Committee : Briefing Document for ZELDOX CAPSULES (Ziprasidone HCl)" (PDF). Fda.gov. July 19, 2000. Retrieved September 30, 2016.

accessdata.fda.gov

"Pharmcology Reviews : 200603" (PDF). Accessdata.fda.gov. Retrieved September 30, 2016.

funnelback.com

tga-search.clients.funnelback.com

"Search the TGA website". Australian Government Department of Health, Therapeutic Goods Administration. Archived from the original on July 16, 2017. Retrieved February 2, 2018.

gov.uk

"Guidance: Antipsychotic medicines". Medicines & Healthcare products Regulatory Agency. August 25, 2005. Retrieved February 2, 2018.

handle.net

hdl.handle.net

Goldstein BI, Baune BT, Bond DJ, Chen PH, Eyler L, Fagiolini A, Gomes F, Hajek T, Hatch J, McElroy SL, McIntyre RS, Prieto M, Sylvia LG, Tsai SY, Kcomt A, Fiedorowicz JG (August 2020). "Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders". Bipolar Disorders. 22 (5): 440–460. doi:10.1111/bdi.12921. hdl:11343/251495. PMC 7522687. PMID 32356562.

healthvermont.gov

"High & Low Blood Sugar". Healthvermont.gov. Retrieved September 30, 2016.

invega.com

"INVEGA Side Effects - Schizophrenia Treatment – INVEGA (paliperidone)". Invega.com. May 17, 2016. Archived from the original on August 17, 2016. Retrieved September 30, 2016.

kcl.ac.uk

kclpure.kcl.ac.uk

Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. (November 2016). "Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?". The British Journal of Psychiatry (Submitted manuscript). 209 (5): 361–365. doi:10.1192/bjp.bp.116.182683. PMID 27802977.

mdedge.com

"Receptor occupancy and drug response: Understanding the relationship". www.mdedge.com. Retrieved October 14, 2022.

medscape.com

emedicine.medscape.com

Soreff S, McInnes LA, Ahmed I, Talavera F (August 5, 2013). "Bipolar Affective Disorder Treatment & Management". Medscape Reference. WebMD. Retrieved October 10, 2013.

reference.medscape.com

"Medscape Multispecialty – Home page". WebMD. Retrieved November 27, 2013.^{[full citation needed]}

mhra.gov.uk

"Medicines Information: SPC & PILs". Medicines and Healthcare products Regulatory Agency. Retrieved February 2, 2018.

nice.org.uk

"Schizophrenia: Full national clinical guideline on core interventions in primary and secondary care" (PDF). Gaskell and the British Psychological Society. National Collaborating Centre for Mental Health. March 25, 2009. Retrieved November 25, 2009.

nih.gov

pubmed.ncbi.nlm.nih.gov

Miyake N, Miyamoto S, Jarskog LF (October 2012). "New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?". Clinical Schizophrenia & Related Psychoses. 6 (3): 122–33. doi:10.3371/CSRP.6.3.4. PMID 23006237.
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842. S2CID 1071537.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
"A roadmap to key pharmacologic principles in using antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 9 (6): 444–54. 2007. doi:10.4088/PCC.v09n0607. PMC 2139919. PMID 18185824.
Tyrer P, Kendall T (January 2009). "The spurious advance of antipsychotic drug therapy". Lancet. 373 (9657): 4–5. doi:10.1016/S0140-6736(08)61765-1. PMID 19058841. S2CID 19951248.
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. (September 2011). "Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis". JAMA. 306 (12): 1359–69. doi:10.1001/jama.2011.1360. PMID 21954480.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H (August 2017). "Treatment of negative symptoms: Where do we stand, and where do we go?" (PDF). Schizophrenia Research. 186: 55–62. doi:10.1016/j.schres.2016.05.015. PMID 27293137. S2CID 4907333.
Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (July 2015). "Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials". Schizophrenia Bulletin. 41 (4): 892–9. doi:10.1093/schbul/sbu170. PMC 4466178. PMID 25528757.
Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, et al. (November 2016). "Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?". The British Journal of Psychiatry (Submitted manuscript). 209 (5): 361–365. doi:10.1192/bjp.bp.116.182683. PMID 27802977.
van Os J, Kapur S (August 2009). "Schizophrenia". Lancet. 374 (9690): 635–45. doi:10.1016/S0140-6736(09)60995-8. PMID 19700006. S2CID 208792724.
Kane JM, Correll CU (2010). "Pharmacologic treatment of schizophrenia". Dialogues in Clinical Neuroscience. 12 (3): 345–57. doi:10.31887/DCNS.2010.12.3/jkane. PMC 3085113. PMID 20954430.
Schultz SH, North SW, Shields CG (June 2007). "Schizophrenia: a review". American Family Physician. 75 (12): 1821–9. PMID 17619525.
Smith T, Weston C, Lieberman J (August 2010). "Schizophrenia (maintenance treatment)". American Family Physician. 82 (4): 338–9. PMID 20704164.
Siskind D, McCartney L, Goldschlager R, Kisely S (November 2016). "Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis". The British Journal of Psychiatry. 209 (5): 385–392. doi:10.1192/bjp.bp.115.177261. PMID 27388573.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH (2015). "A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes". Schizophrenia Bulletin. 41 (6): 1227–1236. doi:10.1093/schbul/sbv125. ISSN 1745-1701. PMC 4601722. PMID 26338693.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B (April 23, 2020). "Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone". The International Journal of Neuropsychopharmacology. 23 (4): 217–229. doi:10.1093/ijnp/pyaa004. ISSN 1469-5111. PMC 7177160. PMID 31974576.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (February 2011). "Increasing off-label use of antipsychotic medications in the United States, 1995-2008". Pharmacoepidemiology and Drug Safety. 20 (2): 177–84. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Geddes J, Freemantle N, Harrison P, Bebbington P (December 2000). "Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis". BMJ. 321 (7273): 1371–6. doi:10.1136/bmj.321.7273.1371. PMC 27538. PMID 11099280.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (September 2005). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". The New England Journal of Medicine. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203.
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. (April 2006). "Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic". The American Journal of Psychiatry. 163 (4): 611–22. doi:10.1176/appi.ajp.163.4.611. PMID 16585435.
Voruganti LP, Baker LK, Awad AG (March 2008). "New generation antipsychotic drugs and compliance behaviour". Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660. S2CID 34935.
Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP (January 2012). "Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications". The International Journal of Risk & Safety in Medicine. 24 (3): 137–46. doi:10.3233/JRS-2012-0567. PMID 22936056.
Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). "Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)". Neuropsychobiology. 57 (1–2): 80–7. doi:10.1159/000135641. PMID 18515977. S2CID 2669203.
Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S (December 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID 21154393.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Nelson JC, Papakostas GI (September 2009). "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials". The American Journal of Psychiatry. 166 (9): 980–91. doi:10.1176/appi.ajp.2009.09030312. PMID 19687129.
Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC (December 2015). "Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study". The American Journal of Psychiatry. 172 (12): 1251–8. doi:10.1176/appi.ajp.2015.14101251. PMC 4843798. PMID 26085041.
Maneeton N, Maneeton B, Srisurapanont M, Martin SD (September 2012). "Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials". BMC Psychiatry. 12: 160. doi:10.1186/1471-244X-12-160. PMC 3549283. PMID 23017200.
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. (August 2004). "A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". Journal of Clinical Psychopharmacology. 24 (4): 365–73. doi:10.1097/01.jcp.0000130557.08996.7a. PMID 15232326. S2CID 36295165.
Roberts RJ, Lohano KK, El-Mallakh RS (September 2016). "Antipsychotics as antidepressants". Asia-Pacific Psychiatry. 8 (3): 179–88. doi:10.1111/appy.12186. PMID 25963405. S2CID 24264818.
Cascade E, Kalali AH, Cummings JL (July 2008). "Use of atypical antipsychotics in the elderly". Psychiatry. 5 (7): 28–31. PMC 2695730. PMID 19727265.
Ventimiglia J, Kalali AH, Vahia IV, Jeste DV (November 2010). "An analysis of the intended use of atypical antipsychotics in dementia". Psychiatry. 7 (11): 14–7. PMC 3010964. PMID 21191528.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–15. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Bishara D, Taylor D (2009). "Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder". Neuropsychiatric Disease and Treatment. 5: 483–90. doi:10.2147/ndt.s5742. PMC 2762364. PMID 19851515.
Taylor DM, Cornelius V, Smith L, Young AH (December 2014). "Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis". Acta Psychiatrica Scandinavica. 130 (6): 452–69. doi:10.1111/acps.12343. PMID 25283309. S2CID 23324764.
Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J (June 2011). "Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials". BMC Psychiatry. 11: 101. doi:10.1186/1471-244X-11-101. PMC 3152513. PMID 21689438.
Kishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials". CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID 23812802. S2CID 11543666.
Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP (February 2003). "Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths". Primary Care Companion to the Journal of Clinical Psychiatry. 5 (1): 6–14. doi:10.4088/PCC.v05n0103. PMC 353028. PMID 15156241.
Uçok A, Gaebel W (February 2008). "Side effects of atypical antipsychotics: a brief overview". World Psychiatry. 7 (1): 58–62. doi:10.1002/j.2051-5545.2008.tb00154.x. PMC 2327229. PMID 18458771.
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC (January 2010). "Impact of FDA black box advisory on antipsychotic medication use". Archives of Internal Medicine. 170 (1): 96–103. doi:10.1001/archinternmed.2009.456. PMC 4598075. PMID 20065205.
Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. (July 2014). "Comparative mortality risks of antipsychotic medications in community-dwelling older adults". The British Journal of Psychiatry. 205 (1): 44–51. doi:10.1192/bjp.bp.112.122499. PMID 23929443.
Steinberg M, Lyketsos CG (September 2012). "Atypical antipsychotic use in patients with dementia: managing safety concerns". The American Journal of Psychiatry. 169 (9): 900–6. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Alevizos B, Papageorgiou C, Christodoulou GN (September 1, 2004). "Obsessive-compulsive symptoms with olanzapine". The International Journal of Neuropsychopharmacology. 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni G, Narayanaswamy JC, Math SB (January 1, 2012). "Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia". Indian Journal of Pharmacology. 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMC 3480803. PMID 23112432.
Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A (September 1, 2000). "Olanzapine and obsessive-compulsive symptoms". European Neuropsychopharmacology. 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610. S2CID 276209.
Schirmbeck F, Zink M (March 1, 2012). "Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review". Current Neuropharmacology. 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMC 3286851. PMID 22942882.
Seeman P (February 2002). "Atypical antipsychotics: mechanism of action". Canadian Journal of Psychiatry. 47 (1): 27–38. doi:10.1177/070674370204700106. PMID 11873706.
Correll CU, Schenk EM (March 2008). "Tardive dyskinesia and new antipsychotics". Current Opinion in Psychiatry. 21 (2): 151–6. doi:10.1097/YCO.0b013e3282f53132. PMID 18332662. S2CID 37288246.
"Consensus development conference on antipsychotic drugs and obesity and diabetes". Diabetes Care. 27 (2): 596–601. February 2004. doi:10.2337/diacare.27.2.596. PMID 14747245.
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, et al. (May 2013). "Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model". Schizophrenia Research. 146 (1–3): 162–9. doi:10.1016/j.schres.2013.02.023. PMID 23499243. S2CID 43719333.
Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A (August 1, 2018). "Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis". Journal of Comparative Effectiveness Research. 7 (8): 737–748. doi:10.2217/cer-2018-0016. ISSN 2042-6305. PMID 29697278. S2CID 13769615.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 1, 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. ISSN 2215-0366. PMC 7029416. PMID 31860457. S2CID 209434994.
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA (2017). "Antipsychotic-associated weight gain: management strategies and impact on treatment adherence". Neuropsychiatr Dis Treat. 13: 2231–2241. doi:10.2147/NDT.S113099. PMC 5574691. PMID 28883731.
Wang Y, Wang D, Cheng J, Fang X, Chen Y, Yu L, Ren J, Tian Y, Zhang C (September 2021). "Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis". Journal of Psychopharmacology. 35 (9): 1111–9. doi:10.1177/02698811211035391. PMID 34311625. S2CID 236451973.
Goldstein BI, Baune BT, Bond DJ, Chen PH, Eyler L, Fagiolini A, Gomes F, Hajek T, Hatch J, McElroy SL, McIntyre RS, Prieto M, Sylvia LG, Tsai SY, Kcomt A, Fiedorowicz JG (August 2020). "Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders". Bipolar Disorders. 22 (5): 440–460. doi:10.1111/bdi.12921. hdl:11343/251495. PMC 7522687. PMID 32356562.
Park YW, Kim Y, Lee JH (December 2012). "Antipsychotic-induced sexual dysfunction and its management". The World Journal of Men's Health. 30 (3): 153–9. doi:10.5534/wjmh.2012.30.3.153. PMC 3623530. PMID 23596605.
Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136. S2CID 262520276.
Holm AC, Edsman I, Lundberg T, Odlind B (June 1993). "Tolerability of remoxipride in the long term treatment of schizophrenia. An overview". Drug Safety. 8 (6): 445–56. doi:10.2165/00002018-199308060-00005. PMID 8329149. S2CID 43855244.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Egerton A, Ahmad R, Hirani E, Grasby PM (November 2008). "Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat". Psychopharmacology. 200 (4): 487–96. doi:10.1007/s00213-008-1226-4. PMID 18597077. S2CID 11800154.
de Boer SF, Koolhaas JM (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". European Journal of Pharmacology. 526 (1–3): 125–39. doi:10.1016/j.ejphar.2005.09.065. PMID 16310183.
King MV, Marsden CA, Fone KC (September 2008). "A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory". Trends in Pharmacological Sciences. 29 (9): 482–92. doi:10.1016/j.tips.2008.07.001. PMID 19086256.
Shahid M, Walker GB, Zorn SH, Wong EH (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". Journal of Psychopharmacology. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID 18308814. S2CID 206489515.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–81. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Wouters W, Tulp MT, Bevan P (May 1988). "Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors". European Journal of Pharmacology. 149 (3): 213–23. doi:10.1016/0014-2999(88)90651-6. PMID 2842163.
Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–6. doi:10.1016/j.autneu.2008.06.004. PMID 18667366. S2CID 20878941.
Weber S, Volynets V, Kanuri G, Bergheim I, Bischoff SC (December 2009). "Treatment with the 5-HT3 antagonist tropisetron modulates glucose-induced obesity in mice". International Journal of Obesity. 33 (12): 1339–47. doi:10.1038/ijo.2009.191. PMID 19823183.
Gobbi G, Janiri L (December 1999). "Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study". European Neuropsychopharmacology. 10 (1): 43–9. doi:10.1016/S0924-977X(99)00055-3. PMID 10647096. S2CID 24251712.
Navari RM (January 2014). "Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting". European Journal of Pharmacology. 722: 180–6. doi:10.1016/j.ejphar.2013.08.048. PMID 24157985.
Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". CNS Drugs. 24 (1): 65–84. doi:10.2165/11202620-000000000-00000. PMID 20030420. S2CID 23464075.
Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
Tanaka O, Kondo T, Otani K, Yasui N, Tokinaga N, Kaneko S (February 1998). "Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects". Therapeutic Drug Monitoring. 20 (1): 117–9. doi:10.1097/00007691-199802000-00021. PMID 9485566.
Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID 6931472.
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50–9. PMID 6143748.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". Arzneimittel-Forschung. 20 (11): 1689–98. PMID 4992598.
Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID 3545764.
Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID 7185768.
Farah A (2005). "Atypicality of atypical antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (6): 268–74. doi:10.4088/PCC.v07n0602. PMC 1324958. PMID 16498489.
Weiden PJ (January 2007). "EPS profiles: the atypical antipsychotics are not all the same". Journal of Psychiatric Practice. 13 (1): 13–24. doi:10.1097/00131746-200701000-00003. PMID 17242588. S2CID 46319827.
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. (October 2006). "Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)". Archives of General Psychiatry. 63 (10): 1079–87. doi:10.1001/archpsyc.63.10.1079. PMID 17015810.
Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM (2023). "Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients". The Primary Care Companion for CNS Disorders. 25 (1): 45835. doi:10.4088/PCC.22m03331. ISSN 2155-7780. PMID 36821764.

ncbi.nlm.nih.gov

"A roadmap to key pharmacologic principles in using antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 9 (6): 444–54. 2007. doi:10.4088/PCC.v09n0607. PMC 2139919. PMID 18185824.
American Geriatrics Society 2012 Beers Criteria Update Expert Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.{{cite journal}}: CS1 maint: numeric names: authors list (link)
Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (July 2015). "Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials". Schizophrenia Bulletin. 41 (4): 892–9. doi:10.1093/schbul/sbu170. PMC 4466178. PMID 25528757.
Kane JM, Correll CU (2010). "Pharmacologic treatment of schizophrenia". Dialogues in Clinical Neuroscience. 12 (3): 345–57. doi:10.31887/DCNS.2010.12.3/jkane. PMC 3085113. PMID 20954430.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH (2015). "A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes". Schizophrenia Bulletin. 41 (6): 1227–1236. doi:10.1093/schbul/sbv125. ISSN 1745-1701. PMC 4601722. PMID 26338693.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B (April 23, 2020). "Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone". The International Journal of Neuropsychopharmacology. 23 (4): 217–229. doi:10.1093/ijnp/pyaa004. ISSN 1469-5111. PMC 7177160. PMID 31974576.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (February 2011). "Increasing off-label use of antipsychotic medications in the United States, 1995-2008". Pharmacoepidemiology and Drug Safety. 20 (2): 177–84. doi:10.1002/pds.2082. PMC 3069498. PMID 21254289.
Geddes J, Freemantle N, Harrison P, Bebbington P (December 2000). "Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis". BMJ. 321 (7273): 1371–6. doi:10.1136/bmj.321.7273.1371. PMC 27538. PMID 11099280.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine. 10 (3): e1001403. doi:10.1371/journal.pmed.1001403. PMC 3595214. PMID 23554581.
Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC (December 2015). "Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study". The American Journal of Psychiatry. 172 (12): 1251–8. doi:10.1176/appi.ajp.2015.14101251. PMC 4843798. PMID 26085041.
Maneeton N, Maneeton B, Srisurapanont M, Martin SD (September 2012). "Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials". BMC Psychiatry. 12: 160. doi:10.1186/1471-244X-12-160. PMC 3549283. PMID 23017200.
Cascade E, Kalali AH, Cummings JL (July 2008). "Use of atypical antipsychotics in the elderly". Psychiatry. 5 (7): 28–31. PMC 2695730. PMID 19727265.
Ventimiglia J, Kalali AH, Vahia IV, Jeste DV (November 2010). "An analysis of the intended use of atypical antipsychotics in dementia". Psychiatry. 7 (11): 14–7. PMC 3010964. PMID 21191528.
Bishara D, Taylor D (2009). "Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder". Neuropsychiatric Disease and Treatment. 5: 483–90. doi:10.2147/ndt.s5742. PMC 2762364. PMID 19851515.
Szegedi A, Zhao J, van Willigenburg A, Nations KR, Mackle M, Panagides J (June 2011). "Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials". BMC Psychiatry. 11: 101. doi:10.1186/1471-244X-11-101. PMC 3152513. PMID 21689438.
Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP (February 2003). "Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths". Primary Care Companion to the Journal of Clinical Psychiatry. 5 (1): 6–14. doi:10.4088/PCC.v05n0103. PMC 353028. PMID 15156241.
Uçok A, Gaebel W (February 2008). "Side effects of atypical antipsychotics: a brief overview". World Psychiatry. 7 (1): 58–62. doi:10.1002/j.2051-5545.2008.tb00154.x. PMC 2327229. PMID 18458771.
Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC (January 2010). "Impact of FDA black box advisory on antipsychotic medication use". Archives of Internal Medicine. 170 (1): 96–103. doi:10.1001/archinternmed.2009.456. PMC 4598075. PMID 20065205.
Steinberg M, Lyketsos CG (September 2012). "Atypical antipsychotic use in patients with dementia: managing safety concerns". The American Journal of Psychiatry. 169 (9): 900–6. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Kulkarni G, Narayanaswamy JC, Math SB (January 1, 2012). "Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia". Indian Journal of Pharmacology. 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMC 3480803. PMID 23112432.
Schirmbeck F, Zink M (March 1, 2012). "Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review". Current Neuropharmacology. 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMC 3286851. PMID 22942882.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 1, 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. ISSN 2215-0366. PMC 7029416. PMID 31860457. S2CID 209434994.
Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA (2017). "Antipsychotic-associated weight gain: management strategies and impact on treatment adherence". Neuropsychiatr Dis Treat. 13: 2231–2241. doi:10.2147/NDT.S113099. PMC 5574691. PMID 28883731.
Satlin A, Durgam S, Vanover KE, Davis RE, Huo J, Mates S, Correll C (May 2020). "M205. Long-Term Safety of Lumateperone (ITI-007): Metabolic Effects in a 1-Year Study". Schizophr Bull. 46 (Suppl 1): S214. doi:10.1093/schbul/sbaa030.517. PMC 7234755.
Goldstein BI, Baune BT, Bond DJ, Chen PH, Eyler L, Fagiolini A, Gomes F, Hajek T, Hatch J, McElroy SL, McIntyre RS, Prieto M, Sylvia LG, Tsai SY, Kcomt A, Fiedorowicz JG (August 2020). "Call to action regarding the vascular-bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders". Bipolar Disorders. 22 (5): 440–460. doi:10.1111/bdi.12921. hdl:11343/251495. PMC 7522687. PMID 32356562.
Park YW, Kim Y, Lee JH (December 2012). "Antipsychotic-induced sexual dysfunction and its management". The World Journal of Men's Health. 30 (3): 153–9. doi:10.5534/wjmh.2012.30.3.153. PMC 3623530. PMID 23596605.
Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
Farah A (2005). "Atypicality of atypical antipsychotics". Primary Care Companion to the Journal of Clinical Psychiatry. 7 (6): 268–74. doi:10.4088/PCC.v07n0602. PMC 1324958. PMID 16498489.

dailymed.nlm.nih.gov

"DailyMed - CAPLYTA- lumateperone capsule". dailymed.nlm.nih.gov. Retrieved January 11, 2023.
"Daily Med – Home page". U.S. National Library of Medicine. Retrieved November 27, 2013.^{[full citation needed]}

otsuka-us.com

"U.S. FDA Approves Otsuka and Lundbeck's REXULTI (Brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia | Discover Otsuka". Otsuka in the U.S. Retrieved October 18, 2018.

pmda.go.jp

ss.pmda.go.jp

"Search". Pharmaceuticals and Medical Devices Agency. Archived from the original on November 16, 2018. Retrieved February 2, 2018.

psychiatrist.com

Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM (2023). "Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients". The Primary Care Companion for CNS Disorders. 25 (1): 45835. doi:10.4088/PCC.22m03331. ISSN 2155-7780. PMID 36821764.

rexulti.com

"REXULTI (brexpiprazole) | Important Safety Information". Rexulti.com. Retrieved September 30, 2016.

rug.nl

pure.rug.nl

Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H (August 2017). "Treatment of negative symptoms: Where do we stand, and where do we go?" (PDF). Schizophrenia Research. 186: 55–62. doi:10.1016/j.schres.2016.05.015. PMID 27293137. S2CID 4907333.

rxwiki.com

"Cariprazine - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol". RxWiki.com. September 17, 2015. Retrieved September 30, 2016.

semanticscholar.org

api.semanticscholar.org

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842. S2CID 1071537.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
Tyrer P, Kendall T (January 2009). "The spurious advance of antipsychotic drug therapy". Lancet. 373 (9657): 4–5. doi:10.1016/S0140-6736(08)61765-1. PMID 19058841. S2CID 19951248.
Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H (August 2017). "Treatment of negative symptoms: Where do we stand, and where do we go?" (PDF). Schizophrenia Research. 186: 55–62. doi:10.1016/j.schres.2016.05.015. PMID 27293137. S2CID 4907333.
van Os J, Kapur S (August 2009). "Schizophrenia". Lancet. 374 (9690): 635–45. doi:10.1016/S0140-6736(09)60995-8. PMID 19700006. S2CID 208792724.
Voruganti LP, Baker LK, Awad AG (March 2008). "New generation antipsychotic drugs and compliance behaviour". Current Opinion in Psychiatry. 21 (2): 133–9. doi:10.1097/YCO.0b013e3282f52851. PMID 18332660. S2CID 34935.
Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE (2008). "Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE)". Neuropsychobiology. 57 (1–2): 80–7. doi:10.1159/000135641. PMID 18515977. S2CID 2669203.
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, et al. (August 2004). "A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features". Journal of Clinical Psychopharmacology. 24 (4): 365–73. doi:10.1097/01.jcp.0000130557.08996.7a. PMID 15232326. S2CID 36295165.
Roberts RJ, Lohano KK, El-Mallakh RS (September 2016). "Antipsychotics as antidepressants". Asia-Pacific Psychiatry. 8 (3): 179–88. doi:10.1111/appy.12186. PMID 25963405. S2CID 24264818.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–15. doi:10.1016/S0140-6736(11)60873-8. PMID 21851976. S2CID 25512763.
Taylor DM, Cornelius V, Smith L, Young AH (December 2014). "Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis". Acta Psychiatrica Scandinavica. 130 (6): 452–69. doi:10.1111/acps.12343. PMID 25283309. S2CID 23324764.
Kishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials". CNS Drugs. 27 (9): 731–41. doi:10.1007/s40263-013-0085-7. PMID 23812802. S2CID 11543666.
Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A (September 1, 2000). "Olanzapine and obsessive-compulsive symptoms". European Neuropsychopharmacology. 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610. S2CID 276209.
Correll CU, Schenk EM (March 2008). "Tardive dyskinesia and new antipsychotics". Current Opinion in Psychiatry. 21 (2): 151–6. doi:10.1097/YCO.0b013e3282f53132. PMID 18332662. S2CID 37288246.
Guenette MD, Giacca A, Hahn M, Teo C, Lam L, Chintoh A, et al. (May 2013). "Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model". Schizophrenia Research. 146 (1–3): 162–9. doi:10.1016/j.schres.2013.02.023. PMID 23499243. S2CID 43719333.
Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A (August 1, 2018). "Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis". Journal of Comparative Effectiveness Research. 7 (8): 737–748. doi:10.2217/cer-2018-0016. ISSN 2042-6305. PMID 29697278. S2CID 13769615.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 1, 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. ISSN 2215-0366. PMC 7029416. PMID 31860457. S2CID 209434994.
Wang Y, Wang D, Cheng J, Fang X, Chen Y, Yu L, Ren J, Tian Y, Zhang C (September 2021). "Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis". Journal of Psychopharmacology. 35 (9): 1111–9. doi:10.1177/02698811211035391. PMID 34311625. S2CID 236451973.
Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs. 15 (4): 329–37, discussion 338. doi:10.2165/00023210-200115040-00006. PMID 11463136. S2CID 262520276.
Holm AC, Edsman I, Lundberg T, Odlind B (June 1993). "Tolerability of remoxipride in the long term treatment of schizophrenia. An overview". Drug Safety. 8 (6): 445–56. doi:10.2165/00002018-199308060-00005. PMID 8329149. S2CID 43855244.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. S2CID 6267180.
Egerton A, Ahmad R, Hirani E, Grasby PM (November 2008). "Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat". Psychopharmacology. 200 (4): 487–96. doi:10.1007/s00213-008-1226-4. PMID 18597077. S2CID 11800154.
Shahid M, Walker GB, Zorn SH, Wong EH (January 2009). "Asenapine: a novel psychopharmacologic agent with a unique human receptor signature". Journal of Psychopharmacology. 23 (1): 65–73. doi:10.1177/0269881107082944. PMID 18308814. S2CID 206489515.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. (July 2010). "Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity". The Journal of Pharmacology and Experimental Therapeutics. 334 (1): 171–81. doi:10.1124/jpet.110.167346. PMID 20404009. S2CID 12893717.
Horiuchi J, McDowall LM, Dampney RA (November 2008). "Role of 5-HT(1A) receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamus activation". Autonomic Neuroscience. 142 (1–2): 71–6. doi:10.1016/j.autneu.2008.06.004. PMID 18667366. S2CID 20878941.
Gobbi G, Janiri L (December 1999). "Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study". European Neuropsychopharmacology. 10 (1): 43–9. doi:10.1016/S0924-977X(99)00055-3. PMID 10647096. S2CID 24251712.
Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". CNS Drugs. 24 (1): 65–84. doi:10.2165/11202620-000000000-00000. PMID 20030420. S2CID 23464075.
Borgström L, Larsson H, Molander L (1982). "Pharmacokinetics of parenteral and oral melperone in man". European Journal of Clinical Pharmacology. 23 (2): 173–6. doi:10.1007/BF00545974. PMID 7140807. S2CID 36697288.
Weiden PJ (January 2007). "EPS profiles: the atypical antipsychotics are not all the same". Journal of Psychiatric Practice. 13 (1): 13–24. doi:10.1097/00131746-200701000-00003. PMID 17242588. S2CID 46319827.

tga.gov.au

ebs.tga.gov.au

"Therapeutic Goods Administration – Home page". Department of Health (Australia). Retrieved November 27, 2013.^{[full citation needed]}

unc.edu

pdsp.med.unc.edu

National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Aug 10]. ChapelHill (NC): University of North Carolina. 1998-2013. Available from: "PDSP Database - UNC". Archived from the original on November 8, 2013. Retrieved May 16, 2016.
Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina. Archived from the original on November 8, 2013. Retrieved October 10, 2013.

cdr.lib.unc.edu

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (September 2005). "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia". The New England Journal of Medicine. 353 (12): 1209–23. doi:10.1056/NEJMoa051688. PMID 16172203.

universitypsychiatry.com

Stahl S. Antipsychotics Explained 1 (PDF). University Psychiatry. Archived from the original (PDF) on November 7, 2017.

uptodate.com

Post RM, Keck P (July 30, 2013). "Bipolar Disorder in adults: Maintenance treatment". UpToDate. Wolters Kluwer Health. Retrieved October 10, 2013.
Stroup TS, Marder S, Stein MB (October 23, 2013). "Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment". UpToDate. Wolters Kluwer. Retrieved October 10, 2013.

web.archive.org

Stahl S. Antipsychotics Explained 1 (PDF). University Psychiatry. Archived from the original (PDF) on November 7, 2017.
"Epinephrine and Norepinephrine". Boundless.com. Archived from the original on October 13, 2016. Retrieved September 30, 2016.
"INVEGA Side Effects - Schizophrenia Treatment – INVEGA (paliperidone)". Invega.com. May 17, 2016. Archived from the original on August 17, 2016. Retrieved September 30, 2016.
National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Aug 10]. ChapelHill (NC): University of North Carolina. 1998-2013. Available from: "PDSP Database - UNC". Archived from the original on November 8, 2013. Retrieved May 16, 2016.
Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina. Archived from the original on November 8, 2013. Retrieved October 10, 2013.
"Search the TGA website". Australian Government Department of Health, Therapeutic Goods Administration. Archived from the original on July 16, 2017. Retrieved February 2, 2018.
"European Medicines Agency: Search". European Medicines Agency. Archived from the original on May 26, 2012. Retrieved February 2, 2018. Search
"Search". Pharmaceuticals and Medical Devices Agency. Archived from the original on November 16, 2018. Retrieved February 2, 2018.

wolterskluwercdi.com

"Comparison of Common Side Effects of Second Generation Atypical Antipsychotics". Facts & Comparisons. Wolters Kluwer Health. Retrieved March 31, 2012.

worldcat.org

search.worldcat.org

Sadock BJ, Sadock, Virginia A., Ruiz, Pedro (2014). Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry (11th ed.). Philadelphia: Wolters Kluwer. p. 318. ISBN 978-1-60913-971-1. OCLC 881019573.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH (2015). "A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes". Schizophrenia Bulletin. 41 (6): 1227–1236. doi:10.1093/schbul/sbv125. ISSN 1745-1701. PMC 4601722. PMID 26338693.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Vázquez-Bourgon J, Suárez-Pinilla P, Romero-Jiménez R, Setién Suero E, Ayesa-Arriola R, Crespo-Facorro B (April 23, 2020). "Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone". The International Journal of Neuropsychopharmacology. 23 (4): 217–229. doi:10.1093/ijnp/pyaa004. ISSN 1469-5111. PMC 7177160. PMID 31974576.
McKim W (2007). "Antipsychotics". Drugs and Behavior: An Introduction to Behavioral Pharmacology (6th ed.). Prentice Hall. pp. 241–260. ISBN 978-0-13-219788-5. OCLC 1301978997.
Alevizos B, Papageorgiou C, Christodoulou GN (September 1, 2004). "Obsessive-compulsive symptoms with olanzapine". The International Journal of Neuropsychopharmacology. 7 (3): 375–377. doi:10.1017/S1461145704004456. ISSN 1461-1457. PMID 15231024.
Kulkarni G, Narayanaswamy JC, Math SB (January 1, 2012). "Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia". Indian Journal of Pharmacology. 44 (5): 649–650. doi:10.4103/0253-7613.100406. ISSN 0253-7613. PMC 3480803. PMID 23112432.
Lykouras L, Zervas IM, Gournellis R, Malliori M, Rabavilas A (September 1, 2000). "Olanzapine and obsessive-compulsive symptoms". European Neuropsychopharmacology. 10 (5): 385–387. doi:10.1016/s0924-977x(00)00096-1. ISSN 0924-977X. PMID 10974610. S2CID 276209.
Schirmbeck F, Zink M (March 1, 2012). "Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review". Current Neuropharmacology. 10 (1): 88–95. doi:10.2174/157015912799362724. ISSN 1570-159X. PMC 3286851. PMID 22942882.
Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A (August 1, 2018). "Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis". Journal of Comparative Effectiveness Research. 7 (8): 737–748. doi:10.2217/cer-2018-0016. ISSN 2042-6305. PMID 29697278. S2CID 13769615.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, Beck K, Natesan S, Efthimiou O, Cipriani A, Howes OD (January 1, 2020). "Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis". The Lancet Psychiatry. 7 (1): 64–77. doi:10.1016/S2215-0366(19)30416-X. ISSN 2215-0366. PMC 7029416. PMID 31860457. S2CID 209434994.
Mattingly G, Matthews-Hayes T, Patel MD, Kramer K, Stahl SM (2023). "Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients". The Primary Care Companion for CNS Disorders. 25 (1): 45835. doi:10.4088/PCC.22m03331. ISSN 2155-7780. PMID 36821764.